bcl2 family changes associated with venetoclax resistance in multiple myeloma
Published 2 years ago • 332 plays • Length 2:41Download video MP4
Download video MP3
Similar videos
-
1:31
bcl2 inhibition with sonrotoclax for treating t(11;14) multiple myeloma
-
1:47
venetoclax and the future of treatment of multiple myeloma
-
3:33
targeting bcl-2 in older aml: novel venetoclax combinations
-
2:30
a new era of treatment for multiple myeloma
-
3:09
bcl2 inhibition and cll: the role of venetoclax
-
4:05
bcl2 and btk dual-inhibition with sonrotoclax zanubrutinib in previously untreated cll and sll
-
2:33
an update on antibody-based treatment approaches in multiple myeloma
-
5:00
comparing btk and bcl-2 inhibitor outcomes in different cll subgroups
-
6:23
how long will i live with multiple myeloma and is there a cure?
-
5:16
mcl-1 protein inhibition: new chemotherapy method 2
-
2:37
second generation cll treatment: zanubrutinib sonrotoclax | constantine tam, md, mbbs | ash 2023
-
5:38
personalized medicine in multiple myeloma
-
2:17
moving towards fixed-duration treatment in multiple myeloma
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
1:26
insight-mm study update: treatment patterns in first and second-line multiple myeloma
-
2:24
synergy: mcl-1 & bcl-2 inhibition for myeloma
-
8:31
targeting bcl-2 in mds
-
0:57
insights into new bite developments in multiple myeloma
-
1:06
safety analysis of the bcl-2 inhibitor venetoclax for cll
-
1:31
evaluating myc, bcl2 and bcl6 expression to define double-expressor lymphoma
-
2:32
changing the way we treat multiple myeloma based on biological markers in 2016
-
2:11
current treatment landscape of newly diagnosed multiple myeloma